AgomAb Therapeutics N.V. American Depositary Shares Accounts Payable

As of the most recent data (June 2026), AGMB shows a accounts payable of $12M. Scroll down for historical charts and peer comparison views.

Tracking AGMB's accounts payable over time shows whether AgomAb Therapeutics N.V. American Depositary Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $12M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has AgomAb Therapeutics N.V. American Depositary Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $12M) with ownership activity and broader fundamentals.

AgomAb Therapeutics N.V. American Depositary Shares's accounts payable is $12M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.